Jungwirth Johannes, Siegert Lisa, Gauthier Lena, Henke Andreas, Krämer Oliver H, Engert Beatrice, Ehrhardt Christina
Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, D-07745 Jena, Germany.
Institute of Toxicology, University Medical Center of the Johannes Gutenberg University Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany.
Int J Mol Sci. 2025 Jul 25;26(15):7185. doi: 10.3390/ijms26157185.
Herpes simplex virus type 1 (HSV-1) has a global prevalence of 64%. Established antiviral drugs, such as acyclovir (ACV), have been successfully used over the past decades. However, due to growing viral resistance against approved antivirals and the lack of effective vaccines, new concepts are essential to target HSV-1 infections. Here, we present data on the inhibitory effect of the procaine-based substance ProcCluster (PC) in reducing HSV-1 replication in vitro. Non-toxic PC concentrations significantly decreased HSV-1 replication in infected cells. Immunofluorescence microscopy revealed an accumulation of viral proteins in early and recycling endosomes, resulting in reduced viral release. The combination of PC with ACV resulted in an enhanced antiviral effect. Based on these results, PC alone, as well as in combination with ACV, appears to be a promising substance with antiviral potential against HSV-1 infections.
单纯疱疹病毒1型（HSV-1）在全球的流行率为64%。在过去几十年中，已成功使用了如阿昔洛韦（ACV）等已有的抗病毒药物。然而，由于病毒对已批准抗病毒药物的耐药性不断增加以及缺乏有效的疫苗，针对HSV-1感染的新概念至关重要。在此，我们展示了基于普鲁卡因的物质ProcCluster（PC）在体外减少HSV-1复制的抑制作用的数据。无毒的PC浓度显著降低了感染细胞中HSV-1的复制。免疫荧光显微镜检查显示病毒蛋白在早期和循环内体中积累，导致病毒释放减少。PC与ACV联合使用产生了增强的抗病毒效果。基于这些结果，单独使用PC以及与ACV联合使用似乎都是具有抗HSV-1感染抗病毒潜力的有前景的物质。
